m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03032)
Name
EPZ015666
Synonyms
EPZ-015666; EPZ 015666
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H25N5O3
InChI
1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16-17,26H,5-6,8-12H2,(H,21,27)(H,22,23,24)/t17-/m0/s1
InChIKey
ZKXZLIFRWWKZRY-KRWDZBQOSA-N
PubChem CID
90241673
TTD Drug ID
D05XQD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Protein arginine methyltransferase 5 (PRMT5)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for EPZ015666. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EPZ015666 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). [1], [2]
References
Ref 1 METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1. J Immunol Res. 2021 Aug 23;2021:6149558. doi: 10.1155/2021/6149558. eCollection 2021.
Ref 2 Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Apr 16;125(16):2530-43. doi: 10.1182/blood-2014-12-619783. Epub 2015 Mar 5.